KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

AbCellera Biologics (ABCL) Other Operating Expenses (2020 - 2023)

AbCellera Biologics' Other Operating Expenses history spans 4 years, with the latest figure at $6.8 million for Q4 2023.

  • For the quarter ending Q4 2023, Other Operating Expenses fell 55.76% year-over-year to $6.8 million, compared with a TTM value of $6.8 million through Sep 2024, down 80.22%, and an annual FY2024 reading of $91.1 million, up 252.84% over the prior year.
  • Other Operating Expenses for Q4 2023 was $6.8 million at AbCellera Biologics, up from $6.1 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $49.6 million in Q1 2022, with the low at $667000.0 in Q3 2020.
  • Average Other Operating Expenses over 4 years is $14.1 million, with a median of $7.6 million recorded in 2021.
  • Year-over-year, Other Operating Expenses soared 2461.13% in 2021 and then tumbled 87.13% in 2023.
  • Tracing ABCL's Other Operating Expenses over 4 years: stood at $32.7 million in 2020, then dropped by 15.36% to $27.7 million in 2021, then tumbled by 44.64% to $15.3 million in 2022, then plummeted by 55.76% to $6.8 million in 2023.
  • Per Business Quant, the three most recent readings for ABCL's Other Operating Expenses are $6.8 million (Q4 2023), $6.1 million (Q3 2023), and $6.5 million (Q2 2023).